Care line · Longevity & peptides
Longevity is what your audience buys next. Own it early.
NAD+, peptides, and optimization protocols — the fastest-growing premium category in consumer health, bought by the people who already buy everything else. Embed Care runs the clinical side under your brand.
Licensed clinician
Longevity & Peptides visits
4.6/5 patient rating
Reviewed in 15–60 min
Why longevity & peptides earns its place
The premium frontier
Longevity buyers are the highest-spend, most-engaged segment in health — and the category is still being claimed.
Protocol-native retention
Cycles, stacks, and monitoring make longevity inherently subscription-shaped.
The halo line
Offering longevity repositions your whole brand upmarket — it sells the menu, not just itself.
The people
Licensed clinicians. Happy patients. Your brand between them.
Every longevity & peptides visit is reviewed by a licensed clinician, routed by state licensure and specialty in 15–60 minutes, around the clock. Patients rate the experience 4.6/5 — under your brand, not ours.
“The protocol arrives with the plan attached — what to take, when, and what we're watching next cycle.”
Longevity program member · illustrativeBuilt for audiences like yours.
Med spas
Anti-aging clients are longevity buyers already.
For med spasGyms & fitness
Recovery and performance protocols fit the floor.
For gyms & fitnessCreators & media
The category defining premium health content.
For creators & mediaThey come for the protocol. They stay for hormones, weight, and primary care — longevity buyers want one place that runs all of it.
Do the math on your audience.
Drag the slider to your reach. At a conservative 2% of people already buying this care, the recurring revenue is yours to keep — we charge flat product rates.
Revenue Engine
Adjust your audience size to see potential returns.
Modeled on a representative blended program mix across care lines — DTC GLP-1 subscriptions alone run ~$199/mo in the market. Illustrative estimate only; actual results vary with conversion, retention, pricing, and medication costs. Not guaranteed earnings.